Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2010 - 2026)

Catalyst Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $132.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 18.58% year-over-year to $132.4 million; the trailing twelve-month figure through Mar 2026 stood at $132.4 million (up 18.58% YoY), and the FY2025 full-year result was $147.2 million, up 21.94% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $132.4 million, down from $147.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $147.2 million in Q4 2025, with the low at $22.5 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $83.6 million across 5 years, with a median of $79.6 million in 2024.
• Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 147.23% — and 2026, when it climbed 18.58%.
• Catalyst Pharmaceuticals' Total Current Liabilities stood at $57.6 million in 2022, then soared by 32.08% to $76.1 million in 2023, then jumped by 58.66% to $120.7 million in 2024, then gained by 21.94% to $147.2 million in 2025, then retreated by 10.03% to $132.4 million in 2026.
• The last three Total Current Liabilities figures came in at $132.4 million (Q1 2026), $147.2 million (Q4 2025), and $128.7 million (Q3 2025), per Business Quant data.